Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McMahon, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMahon, G.
The Oncologist, Vol. 5, Suppl 1, 3-10, April 2000
© 2000 AlphaMed Press

SUPPLEMENT

VEGF Receptor Signaling in Tumor Angiogenesis

Gerald McMahon

SUGEN, Inc., South San Francisco, California, USA

Correspondence: Gerald McMahon, Ph.D., Vice President, Drug Discovery, SUGEN, Inc., 230 East Grand Avenue, South San Francisco, California 94080, USA. Telephone: 650-553-8774; Fax: 650-553-8307; e-mail: Jerry-mcmahon{at}SUGEN.com

The growth of human tumors and development of metastases depend on the de novo formation of blood vessels. The formation of new blood vessels is tightly regulated by specific growth factors that target receptor tyrosine kinases (RTKs). Vascular endothelial growth factor (VEGF) and the Flk-1/KDR RTK have been implicated as the key endothelial cell-specific factor signaling pathway required for pathological angiogenesis, including tumor neovascularization. Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood vessel formation in growing tumors, leading to stasis or regression of tumor growth. Advances in understanding the biology of angiogenesis have led to the development of several therapeutic modalities for the inhibition of the VEGF tyrosine kinase signaling pathway. A number of these modalities are under investigation in clinical studies to evaluate their potential to treat human cancers.

Key Words. Angiogenesis • Vascular endothelial growth factor (VEGF) • Tyrosine kinase receptors • Tyrosine kinase inhibitors




This article has been cited by other articles:


Home page
 Exp Biol MedHome page
B. B. Aggarwal, M. E. Van Kuiken, L. H. Iyer, K. B. Harikumar, and B. Sung
Molecular Targets of Nutraceuticals Derived from Dietary Spices: Potential Role in Suppression of Inflammation and Tumorigenesis
Exp Biol Med, August 1, 2009; 234(8): 825 - 849.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. H. Jung, S. H. Lee, E.-M. Ahn, and Y. M. Lee
Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway
Carcinogenesis, April 1, 2009; 30(4): 655 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu
Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer
Cancer Res., October 1, 2008; 68(19): 7750 - 7759.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Rodriguez-Porcel, W. Cai, O. Gheysens, J. K. Willmann, K. Chen, H. Wang, I. Y. Chen, L. He, J. C. Wu, Z.-b. Li, et al.
Imaging of VEGF Receptor in a Rat Myocardial Infarction Model Using PET
J. Nucl. Med., April 1, 2008; 49(4): 667 - 673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al.
Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Cancer Res., March 15, 2008; 68(6): 1916 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr
P-glycoprotein: So Many Ways to Turn It On
J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 247 - 253.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Chakraborty, S. Jain, and G. C. Kundu
Osteopontin Promotes Vascular Endothelial Growth Factor Dependent Breast Tumor Growth and Angiogenesis via Autocrine and Paracrine Mechanisms
Cancer Res., January 1, 2008; 68(1): 152 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum
Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel.
Cancer Res., November 15, 2006; 66(22): 10919 - 10928.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Carducci, L. Musib, M. S. Kies, R. Pili, M. Truong, J. R. Brahmer, P. Cole, R. Sullivan, J. Riddle, J. Schmidt, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol., September 1, 2006; 24(25): 4092 - 4099.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Su, Q. Zheng, M. M. Vaughan, Y. Bu, and I. H. Gelman
SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor Inhibition
Cancer Res., June 1, 2006; 66(11): 5599 - 5607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Siemann, M. C. Bibby, G. G. Dark, A. P. Dicker, F. A.L.M. Eskens, M. R. Horsman, D. Marme, and P. M. LoRusso
Differentiation and Definition of Vascular-Targeted Therapies
Clin. Cancer Res., January 15, 2005; 11(2): 416 - 420.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Nakamura, A. Yamamoto, M. Kamishohara, K. Takahashi, E. Taguchi, T. Miura, K. Kubo, M. Shibuya, and T. Isoe
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth
Mol. Cancer Ther., December 1, 2004; 3(12): 1639 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-K. Min, K.-Y. Han, E.-C. Kim, Y.-M. Kim, S.-W. Lee, O.-H. Kim, K.-W. Kim, Y. S. Gho, and Y.-G. Kwon
Capsaicin Inhibits in Vitro and in Vivo Angiogenesis
Cancer Res., January 15, 2004; 64(2): 644 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
D. J. Moshinsky, L. Ruslim, R. A. Blake, and F. Tang
A Widely Applicable, High-Throughput TR-FRET Assay for the Measurement of Kinase Autophosphorylation: VEGFR-2 as a Prototype
J Biomol Screen, August 1, 2003; 8(4): 447 - 452.
[Abstract] [PDF]

Home page
 Mol Cancer ResHome page
R. K. Nuttall, C. J. Pennington, J. Taplin, A. Wheal, V. W. Yong, P. A. Forsyth, and D. R. Edwards
Elevated Membrane-Type Matrix Metalloproteinases in Gliomas Revealed by Profiling Proteases and Inhibitors in Human Cancer Cells
Mol. Cancer Res., March 1, 2003; 1(5): 333 - 345.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
Y. Li and F. H. Sarkar
Gene Expression Profiles of Genistein-Treated PC3 Prostate Cancer Cells
J. Nutr., December 1, 2002; 132(12): 3623 - 3631.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-M. Kim, S. Hwang, Y.-M. Kim, B.-J. Pyun, T.-Y. Kim, S.-T. Lee, Y. S. Gho, and Y.-G. Kwon
Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1
J. Biol. Chem., July 26, 2002; 277(31): 27872 - 27879.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song
Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response
Cancer Res., March 1, 2002; 62(6): 1702 - 1706.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. Rao, B. Puschner, and T. A. Prolla
Gene Expression Profiling of Low Selenium Status in the Mouse Intestine: Transcriptional Activation of Genes Linked to DNA Damage, Cell Cycle Control and Oxidative Stress
J. Nutr., December 1, 2001; 131(12): 3175 - 3181.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist, October 1, 2001; 6(2008): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M. Faul
Antiangiogenic and Antitumor Effects of a Protein Kinase C{beta} Inhibitor in Human T98G Glioblastoma Multiforme Xenografts
Clin. Cancer Res., March 1, 2001; 7(3): 634 - 640.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H.-P. Gerber, J. Kowalski, D. Sherman, D. A. Eberhard, and N. Ferrara
Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth
Cancer Res., November 1, 2000; 60(22): 6253 - 6258.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2000 by AlphaMed Press.
Advertisement